Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote about identites, and how “patient with IPF” is just one of many identities she has. Charlene talks about the importance of not making your disease identity a prominent one, however, she also talks about how it is important to tell others about her disease in order to be set up for success or accommodated when she needs it.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study which examined the prognosis in patients with combined pulmonary fibrosis and emphysema (CPFE) after an acute exacerbation. This study revealed that patients with idiopathic pulmonary fibrosis (IPF) who had an acute exacerbation were significantly worse than those with CPFE.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she recently wrote about measuring productivity differently as a patient with IPF. She now focuses on measuring productivity by the quality of accomplishments she achieves versus the quantity.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study recently published by the UK. This study sought to understand the pattern of signs and symptoms leading up to a diagnosis of idiopathic pulmonary fibrosis (IPF). The results indicated a lag between when the symptoms were first recognized in patients and when they are ultimately diagnosed with IPF.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column from her colleague Christie Patient, who is a caregiver for her Mom who received a double lung transplant. Christie writes about what she learnt as an unexpected caregiver through her Mom’s experience with IPF and lung transplant in a creative, honest and inspiring way. She offers a unique perspective and gives a voice to new caregivers through this open letter.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing results from a study on the effectiveness and safety of using Esbriet as a treatment for idiopathic pulmonary fibrosis (IPF). The study, conducted in Poland, allowed researchers to analyze data from 307 patients with IPF, revealing pirfenidone’s long-term acceptable safety and efficacy profiles.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on her personal experience with COVID-19. Like many others living with a chronic lung condition, Charlene Marshall was deeply fearful of COVID-19 but now feels obligated to share her experience with the IPF/PF community through this column.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article examining the link between patients with interstitial lung disease (ILDs) and ischaemic heart disease or myocardial infarction (heart attack). Many patients living with idiopathic pulmonary fibrosis (IPF), the most common type of ILD, find themselves navigating heart problems as well, which is reflective in the study, “Interstitial lung disease is a risk factor for ischaemic heart disease and myocardial infarction” (2019). Further understanding these risk factors and the relationship between ILDs and heart disease allows clinicians to better assess and manage the cardiovascular needs of patients.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a recent column she wrote about calming our anxieties amidst the COVID-19 pandemic. Patients living with idiopathic pulmonary fibrosis (IPF) are considered high-risk for catching the virus, and experiencing critical complications as a result. This can be frightening so Charlene Marshall encourages all patients with IPF to focus on their mental health during this scary time. See some of the tips she has suggested for combating anxieties, and feel free to share and add your own.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com

Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a news article summarizing a study published in the American Journal of Respiratory and Critical Care Medicine. Researchers from the University of Leicester and the University of Nottingham, both located in the UK, revealed three new gene variants that are associated with idiopathic pulmonary fibrosis (IPF). Identifying and further understanding these genes will not only helps scientists improve their understanding of IPF, but also help them develop new treatments for the large number of people living with this disease around the world.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com